| Recent advances in metal nanoparticles in cancer therapy |
30 |
| Chitosan-based nanoparticles as drug delivery systems: a review on two decades of research |
26 |
| Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy |
22 |
| Application of titanium dioxide (TiO2) nanoparticles in cancer therapies |
19 |
| General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes |
18 |
| Targeting of microbubbles: contrast agents for ultrasound molecular imaging |
17 |
| Liposome: composition, characterisation, preparation, and recent innovation in clinical applications |
17 |
| RGD peptide-based non-viral gene delivery vectors targeting integrin alpha(v)beta(3) for cancer therapy |
16 |
| Novel advances in targeted drug delivery |
15 |
| CD133: beyond a cancer stem cell biomarker |
15 |
| Stimuli-responsive nanoscale drug delivery systems for cancer therapy |
14 |
| Advances in nano-delivery systems for doxorubicin: an updated insight |
14 |
| Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice |
13 |
| Drug development for Alzheimer's disease: review |
13 |
| Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an in-vitro, in-vivo and mechanistic investigation |
13 |
| Promising effects of nanomedicine in cancer drug delivery |
12 |
| Recent advances in kartogenin for cartilage regeneration |
12 |
| The promising potentials of capped gold nanoparticles for drug delivery systems |
12 |
| Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer |
11 |
| Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles |
11 |
| Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease? |
11 |
| Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia |
10 |
| Selective induction of apoptosis in MCF7 cancer-cell by targeted liposomes functionalised with mannose-6-phosphate |
10 |
| In vitro and in vivo assessment of polymer microneedles for controlled transdermal drug delivery |
10 |
| Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis |
10 |
| Gold-capped mesoporous silica nanoparticles as an excellent enzyme-responsive nanocarrier for controlled doxorubicin delivery |
9 |
| Precise tuning of disulphide crosslinking in mRNA polyplex micelles for optimising extracellular and intracellular nuclease tolerability |
9 |
| MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma |
9 |
| Phytochemical based nanomedicines against cancer: current status and future prospects |
9 |
| Drug delivery targets and systems for targeted treatment of rheumatoid arthritis |
9 |
| Microneedles containing cross-linked hyaluronic acid particulates for control of degradation and swelling behaviour after administration into skin |
9 |
| NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway |
9 |
| Oral self-emulsifying delivery systems for systemic administration of therapeutic proteins: science fiction? |
8 |
| Doxorubicin-conjugated D-glucosamine- and folate- bi-functionalised InP/ZnS quantum dots for cancer cells imaging and therapy |
8 |
| Anticancer activity of polyphyllin I in nasopharyngeal carcinoma by modulation of lncRNA ROR and P53 signalling |
8 |
| Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need |
8 |
| Recent advances in ultrasound-triggered therapy |
8 |
| The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation |
8 |
| Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway |
7 |
| Lipid-coated calcium phosphate nanoparticle and beyond: a versatile platform for drug delivery |
7 |
| Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels |
7 |
| Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis |
7 |
| cRGD functionalised nanocarriers for targeted delivery of bioactives |
7 |
| Mesoporous silica-coated gold nanostars with drug payload for combined chemo-photothermal cancer therapy |
7 |
| Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex |
7 |
| Long-chain triglycerides-based self-nanoemulsifying oily formulations (SNEOFs) of darunavir with improved lymphatic targeting potential |
7 |
| LOX/LOXL in pulmonary fibrosis: potential therapeutic targets |
7 |
| Graphene-based nanocomposites: synthesis and their theranostic applications |
7 |
| Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer |
7 |
| Coenzyme Q10 and retinaldehyde co-loaded nanostructured lipid carriers for efficacy evaluation in wrinkles |
7 |
